Publish Your Research Online
Get Recognition - International Audience
Request for an Author Account | Login | Submit Article
|HOME||FAQ||TOP AUTHORS||FORUMS||PUBLISH ARTICLE|
The Battle: Microbes versus Vaccines, Antibiotics and AntipathogensBY: Vipin Chandra Kalia | Category: Environmental-Biotechnology | Submitted: 2016-09-14 10:18:28
Article Summary: "The ubiquitous nature of microbes reflects upon their metabolic diversity and ability to evolve rapidly to counter any environmental stress. They are bestowed with a unique arsenal to infect eukaryotic cells leading to the disease condition. Strategies have been developed to fight diseases: (i) vaccines to prevent bacterial atta.."
The Microbial Pathogens
Bacteria are unicellular and are thought to live alone and in isolation. They are perceived to be introverts and arrogant. However, bacterial multiply and live together in large numbers as colonies. They also exist as communities, where diverse bacteria may live together and help each other. However, they have well developed defense mechanisms, which enable them to survive through stress conditions and maintain their integrity. Pathogenic microbes infect human beings and cause a wide range of diseases. The worry of the Health Departments is: How to handle this ever evolving battle between human beings and pathogenic microbes?
Countering Microbial Arsenal
A variety of approaches have been tried to counter microbial attack: (i) the Vaccines, (ii) the Antibiotics, and (iii) the Antipathogens.
The Vaccine Way
Vaccines are biological responses, which enable living beings to acquire immunity against specific diseases. Here, the body is prepared for protecting itself in anticipation of any microbial threat. The microbe - killed form or made less or non-virulent stimulates the body's immune system. These are either prophylactic, which prevents future infectious attacks or therapeutic. Although, vaccines have proved effective in fighting infectious diseases, however, certain limitations exist - inadequate immune response, or genetic (lack of B cells to generate antibodies). The vaccines may show adverse effects: fever, pain, muscular cramps, etc. In India, vaccines against polio have proved to be a great success.
The Antibiotic Way
Deadly diseases caused by strains of Clostridium, Yersinia, Streptococcus, and Staphylococcus species have been responsible for the epidemic witnessed in the 18th century. Discovery of antibiotics was a great relief, which brought hope to humanity. Sir Alexander Fleming discovered the wonder drug - the antibiotic - penicillin. However, the signs of hope started fading with the emergence of strains of Staphylococcus resistant to penicillin. Later on, Shigella strains resistant to tetracycline, and Streptococcus strains to erythromycin were reported. This provoked medical practitioners to prescribe higher doses of antibiotics. Bacteria reacted to this unwarranted stress and evolved drug resistance. The continuous emergence of antibiotic resistant bacteria discouraged researchers. Soon Pharmaceutical companies also started thinking of dis-investing in this area.
The Antipathogen Way
Bacteria, which cause infectious diseases, are bestowed with certain unique characteristics. At low cell densities, they don't express genes which will provoke human immune system to get activated. Initially, they maintain a low profile to evade human immune system. They become virulent by expressing genes responsible for pathogenicity, only at high cell densities, a phenomenon termed as quorum sensing (QS). The phenotype, which proves highly effective in protecting bacteria from any attack, is the formation of biofilm. Within the biofilm, bacteria behave like highly antibiotic resistant forms. In comparison to their planktonic counter parts, they may show up to 1000 times more resistance to antibiotics.
In Nature, microbes exploit QS to produce antibiotics and toxins, which have the potential to kill other microbes in their vicinity. These rival organisms produce molecules, which act as QS inhibitors (QSIs). R&D efforts have revealed bacteria like Pseudomonas, Ralstonia, Acinetobacter, Arthrobacter, Comamononas, Tenacibaculum Rhodococcus, Bacillus, Oceanobacillus, and Streptomyces, to produce QSIs. On the other hand, certain plants including legumes and medicinal plants produce secondary metabolites, which act as QSIs. These QSIs can disrupt biofilms and expose bacteria, which then become susceptible to lower doses of antibiotics. These QSIs can thus treat bacterial infections. Since these molecules don't cause any unnecessary stress on bacterial growth, the risk of their developing resistance to QSIs is quite low.
Among the different molecules, which can act as QSIs, the most attractive are the enzymes: (i) acylhomoserine lactone - lactonase (AHL-lactonase), and (ii) AHL-acylases. These enzymes inactivate the QS signal molecules - acylhomoserine lactones (AHL), which are composed of a lactone ring and a variable carbon (C) length acyl chain. AHL-lactonases act by breaking open the lactone ring of the AHL molecule, where as AHL-acylases act by cleaving the acyl side chain. AHL-lactonases have a greater advantage as they are independent of acyl chain length, where as AHL-acylases are chain length specific.
The best bet
Bacillus is generally regarded as safe organisms. It has a great ability to produce AHL-lactonases. These have been reported to be effective in: (i) protecting fish from pathogenic bacteria such as Vibrio species, and (ii) preventing biofouling of membranes used for treating drinking water, etc.
1. Agarwala M, Choudhury B, Yadav RNS (2014) Comparative study of antibiofilm activity of copper oxide and iron oxide nanoparticles against multidrug resistant biofilm forming uropathogens. Indian J Microbiol 54:365-368. doi: 10.1007/s12088-014-0462-z
2. Alipiah NM, Shamsudin MN, Yusoff FM, Arshad A (2015) Membrane biosynthesis gene disruption in methicillin-resistant Staphylococcus aureus (MRSA) as potential mechanism for reducing antibiotic resistance. Indian J Microbiol 54:41-49. doi: 10.1007/s12088-014-0488-2
3. Arasu MV, Al-Dhabi NA, Rejiniemon TS, Lee KD, Huxley VAJ, Kim DH, Duraipandiyan V, Karuppiah P, Choi KC (2015) Identification and characterization of Lactobacillus brevis P68 with antifungal, antioxidant and probiotic functional properties. Indian J Microbiol 55:19-28. doi: 10.1007/s12088-014-0495-3
4. Gui Z, Wang H, Ding T, Zhu W, Zhuang X, Chu W (2014) Azithromycin reduces the production of α-hemolysin and biofilm formation in Staphylococcus aureus. Indian J Microbiol 54:114-117. doi: 10.1007/s12088-013-0438-4
5. Hema M, Balasubramanian S, Princy SA (2015) Meddling Vibrio cholerae murmurs: A neoteric advancement in cholera research. Indian J Microbiol 55:121-130. doi:10.1007/s12088-015-0520-1
6. Huma N, Shankar P, Kushwah J, Bhushan A, Joshi J, Mukherjee T, Raju SC, Purohit HJ, Kalia VC (2011) Diversity and polymorphism in AHL-lactonase gene (aiiA) of Bacillus. J Microbiol Biotechnol 21:1001-1011. doi:10.4014/jmb.1105.05056
7. Kalia VC (2013) Quorum sensing inhibitors: an overview. Biotechnol Adv 31:224-245. doi:10.1016/j.biotechadv.2012.10.004
8. Kalia VC (2014) In search of versatile organisms for quorum‐sensing inhibitors: acyl homoserine lactones (AHL)‐acylase and AHL‐lactonase. FEMS Microbiology Letters 359:143. doi: 10.1111/1574-6968.12585
9. Kalia VC (2014) Microbes, antimicrobials and resistance: The battle goes on. Indian J Microbiol 54:1-2. doi: 10.1007/s12088-013-0443-7
10. Kalia VC (2015) Quorum Sensing vs Quorum Quenching: A Battle with No End in Sight. http://link.springer.com/book/10.1007/978-81-322-1982-8
11. Kalia VC (2015) Microbes: The most friendly beings? In: Quorum Sensing vs Quorum Quenching: A Battle with No End in Sight, 1-5. Editor: VC Kalia. Springer India. doi:10.1007/978-81-322-1982-8_1
12. Kalia VC, Prakash J, Koul S, Ray S (2016) Simple and rapid method for detecting biofilm forming bacteria. Indian J Microbiol 56:1-3. doi: 10.1007/s12088-016-0616-2
13. Kalia VC, Kumar P (2015) Genome wide search for biomarkers to diagnose Yersinia infections. Indian J Microbiol 55:366-374. doi: 10.1007/s12088-015-0552-6
14. Kalia VC, Kumar P, Kumar R, Mishra A, Koul S (2015) Genome wide analysis for rapid identification of Vibrio species. Indian J Microbiol 55:375-383. doi: 10.1007/s12088-015-0553-5
15. Kalia VC, Kumar P, Pandian SK, Sharma P (2014) Biofouling control by quorum quenching. Hb_25 Springer Handbook of Marine Biotechnology Chapter 15:431-440. Springer Ed. S. K. Kim.
16. Kalia VC, Purohit HJ (2011) Quenching the quorum sensing system: potential antibacterial drug targets. Crit Rev Microbiol 37:121-140. doi: 10.3109/1040841X.2010.532479
17. Kalia VC, Raju SC, Purohit HJ (2011) Genomic analysis reveals versatile organisms for quorum quenching enzymes: Acyl-homoserine lactone-acylase and -lactonase. Open Microbiol J 5:1-13. doi:10.2174/1874285801105010001
18. Kalia VC, Rani A, Lal S, Cheema S, Raut CP (2007) Combing databases reveals potential antibiotic producers. Expert Opin Drug Discov 2:211-224. doi:10.1517/17460418.104.22.168
19. Kalia VC, Wood TK, Kumar P (2014) Evolution of resistance to quorum-sensing inhibitors. Microb Ecol 68:13-23. doi:10.1007/s00248-013-0316-y
20. Kalia VC, Kumar P (2015) Potential applications of quorum sensing inhibitors in diverse fields. In: Quorum Sensing vs Quorum Quenching: A Battle with No End in Sight, 359-370. Editor: VC Kalia. Springer India. doi:10.1007/978-81-322-1982-8_29
21. Kalia VC, Kumar P (2015) The Battle: Quorum-sensing inhibitors versus evolution of bacterial resistance. In: Quorum Sensing vs Quorum Quenching: A Battle with No End in Sight, 385-391. Editor: VC Kalia. Springer India. doi:10.1007/978-81-322-1982-8_31
22. Kaur G, Rajesh S, Princy SA (2015) Plausible drug targets in the Streptococcus mutans quorum sensing pathways to combat dental biofilms and associated risks. Indian J Microbiol 55:349-357. doi:10.1007/s12088-015-0534-8
23. Koul S, Kumar P, Kalia VC (2015) A unique genome wide approach to search novel markers for rapid identification of bacterial pathogens. J Mol Genet Med 9:194. doi: 10.4172/1747-0862.1000194
24. Koul S, Prakash J, Mishra A, Kalia VC (2016) Potential emergence of multi-quorum sensing inhibitor resistant (MQSIR) bacteria. Indian J Microbiol 56:1-18. doi: 10.1007/s12088-015-0558-0
25. Kumar P, Koul S, Patel SKS, Lee JK, Kalia VC (2015) Heterologous expression of quorum sensing inhibitory genes in diverse organisms. In: Quorum Sensing vs Quorum Quenching: A Battle with No End in Sight, 343-356. Editor: VC Kalia. Springer India. doi:10.1007/978-81-322-1982-8_28
26. Kumar P, Patel SKS, Lee JK, Kalia VC (2013) Extending the limits of Bacillus for novel biotechnological applications. Biotechnol Adv 31:1543-1561. doi:10.1016/j.biotechadv.2013.08.007
27. Mahale KN, Paranjape PS, Marathe NP, Dhotre DP, Chowdhury S, Shetty SA, Sharma A, Sharma K, Tuteja U, Batra HV, Shouche YS (2014) Draft genome sequences of Yersinia pestis strains from the 1994 plague epidemic of Surat and 2002 Shimla outbreak in India. Indian J Microbiol 54:480-482. doi: 10.1007/s12088-014-0475-7
28. Moroeanu VI, Vamanu E, Paun G, Neagu E, Ungureanu OR, Eremia SAV, Radu GL, Ionescu R, Pelinescu DR (2015) Probiotic strains influence on infant microbiota in the in vitro colonic fermentation model GIS1. Indian J Microbiol 55:423-429. doi: 10.1007/s12088-015-0542-8
29. Prakasham RS, Kumar BS, Kumar YS, Kumar KP (2014) Production and characterization of protein encapsulated silver nanoparticles by marine isolate Streptomyces parvulus SSNP11. Indian J Microbiol 54:329-336. doi: 10.1007/s12088-014-0452-1
30. Purohit HJ, Cheema S, Lal S, Raut CP, Kalia VC (2007) In search of drug targets for Mycobacterium tuberculosis. Infect Disord Drug Targets 7:245-250. doi: 10.2174/187152607782110068
31. Saxena A, Mukherjee M, Kumari R, Singh P, Lal R (2014) Synthetic biology in action: Developing a drug against MDR-TB. Indian J Microbiol 54:369-375. doi:10.1007/s12088-014-0498-0
32. Shang Z, Wang H, Zhou S, Chu W (2014) Characterization of N-acyl-homoserine lactones (AHLs)-deficient clinical isolates of Pseudomonas aeruginosa. Indian J Microbiol 54:158-162. doi: 10.1007/s12088-014-0449-9
33. Wang R, Fang S, Xiang S, Ling S, Yuan J, Wang S (2014) Generation and characterization of a scFv antibody against T3SS needle of Vibrio parahaemolyticus. Indian J Microbiol 54:143-150. doi: 10.1007/s12088-013-0428-6
About Author / Additional Info:
Researcher in Microbial Biotechnology and Genomics at CSIR-IGIB, Delhi.
Comments on this article: (0 comments so far)
• The Battle: Microbes versus Vaccines, Antibiotics and Antipathogens
• Parallel Potential Prospects of Nanotechnology and Bioinformatics
• Phytochemical Analysis: Metabolic Profiling Techniques
• Agarose Gel Electrophoresis
Latest Articles in "Environmental-Biotechnology" category:
• Advantages and Disadvantages of Biofuels
• Phytoremediation For Heavy Metals
• Biotechnology For a Clean Environment
• Methods of Wastewater Treatment
• Steps Involved in Nitrogen Cycle
• Biotechnology and Environment Protection
• Greenhouse Effect - Importance and Types
• Biological Degradation of Xenobiotics
• Phytoremediation - Greener Approach to Control Pollution
• Impact of Waste Management
• Waste Water Treatment Steps: Primary, Secondary and Tertiary Treatment
• Bioremediation - A Weapon to Tackle Oil Spills
• Phytoremediation - Use of green plants to remove pollutants
• The History of Botany | Botanists in Philippines
• Bioremediation by Cold Tolerant Microbes
• Cold Adaptation by Microorganisms
• Succession Stages of Xerosere
• The Climax Concept - Theories and Categories
• Succession Stages of Hydrosere
Important Disclaimer: All articles on this website are for general information only and is not a professional or experts advice. We do not own any responsibility for correctness or authenticity of the information presented in this article, or any loss or injury resulting from it. We do not endorse these articles, we are neither affiliated with the authors of these articles nor responsible for their content. Please see our disclaimer section for complete terms.
Copyright © 2010 biotecharticles.com - Do not copy articles from this website.
ARTICLE CATEGORIES :
| Disclaimer/Privacy/TOS | Submission Guidelines | Contact Us